Autopsy report · NCT02968641

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

“This study was initially planned to enroll patients in Mongolia. However, due to challenges in setting it up in Mongolia, this study was later determined not to be initiated.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Eiger BioPharmaceuticals

Sponsor type

Industry

Conditions

Chronic Delta Hepatitis

Interventions

Lonafarnib; Ritonavir

Participants

0

Trials that died the same way

• Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery
  “The study was stopped due to difficulties in including patients” (58% match in meaning)
• RCT Between UPP and Controls in Adult OSA
  “No patients have been enrolled, and will not. The study was never started” (57% match in meaning)
• Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology
  “Enrollment considerations and current status of the clinical study” (56% match in meaning)
• Ischemic Stroke and Early Vertical Positioning (SEVEL)
  “The required number of patients was not reached. The sites were not able to include more patients.Despite several actions the stop of the study has been decided” (56% match in meaning)
• A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole
  “No suitable patients and many patients refused the study” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.